The Bayer Group continued its strong upward trend in the Life Science business - HealthCare and CropScience - for the third quarter of 2014.
"We saw robust sales growth for our recently launched pharmaceutical products and in our CropScience business in North and Latin America," said Bayer Management Board Chairman, Dr. Marijn Dekkers.
Sales of the Bayer Group rose by 5.6% in the third quarter of 2014 to EUR 10,187 million. Gross cash flow rose by 9.1% to EUR 1,492 million due to improvement in EBITDA, while cash flow moved ahead by 5.1% to EUR 1,816 million. Net financial debt declined from EUR 9.9 billion on June 20, 2014, to EUR 8.5 billion on September 30, 2014.
Sales in the Consumer Health segment rose by 2.4% to EUR 1,921 million. This increase was driven by the Consumer Care and Animal Health divisions. In the Animal Health Division, sales of the Seresto™ flea and tick collar in Europe developed particularly well.
No comments:
Post a Comment